Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brexpiprazole (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms EQUATOR
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 31 Jul 2018 According to a Lundbeck A/S media release, the European Commission has approved Rxulti (brexpiprazole) for the treatment of schizophrenia in adults.
    • 01 Jun 2018 According to a Lundbeck A/S media release, Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion on Rxulti (brexpiprazole) for the treatment of schizophrenia in adults. A final decision from the European Commission is expected within 67 days.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top